Skip to main content

Context Therapeutics Inc.

corporate_fare Company Profile

Context Therapeutics Inc.

CNTX·NASDAQ·Life Sciences·CIK 0001842952

Context Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing T cell engaging (TCE) bispecific antibodies (bsAb) for solid tumors. The company aims to build a portfolio of these TCE bispecific therapeutics. Its pipeline includes CTIM-76, a Claudin 6 (CLDN6) x CD3 TCE, CT-95, a Mesothelin (MSLN) x CD3 TCE, and CT-202, a Nectin cell adhesion protein 4 (Nectin-4) x CD3 TCE. CTIM-76 is designed to redirect T-cell-mediated lysis towards malignant cells expressing CLDN6, a protein found in multiple solid tumors and at low levels or absent in healthy adult tissues. IND-enabling studies for CTIM-76 have been completed. On May 2, 2024, the U.S. Food and Drug Administration (FDA) cleared the company's IND application for a Phase 1 dose escalation and expansion trial of CTIM-76 in patients with CLDN6-positive gynecologic and testicular cancers. The first patient in this trial was dosed in January 2025. Phase 1a interim data for the CTIM-76 trial are expected in June 2026. CT-95 is an MSLN x CD3 TCE intended to redirect T-cell-mediated lysis towards malignant cells expressing MSLN, a membrane protein overexpressed in approximately 30% of cancers. The first patient in the CT-95 Phase 1 trial was dosed in April 2025. Phase 1a interim data for the CT-95 trial are expected in September 2026. CT-202 is a Nectin-4 x CD3 TCE that targets Nectin-4, a cell surface protein frequently overexpressed in various solid tumors, including bladder, colorectal, lung, and breast cancers. Nectin-4 is a clinically validated target for cancer therapy, though traditional antibody-drug conjugates (ADCs) targeting it are associated with adverse events like neuropathy and rash. CT-202 is a pH-dependent TCE designed for preferential activity within the tumor microenvironment. The company submitted an application to the Australian Bellberry Human Research Ethics Committee (HREC) in March 2026 to support the initiation of a first-in-human trial for CT-202.

Context Therapeutics Inc. (NASDAQ:CNTX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for CNTX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 16 rated 8 or above. Recent SEC coverage for CNTX spans 10-Q, 8-K, DEF 14A, PRE 14A.

Recent high-impact activity:

  • CTIM-76 Shows 22% ORR in Platinum-Resistant Ovarian Cancer as Cash Runs to Early Q4 2027
  • Context Therapeutics Q3: Going Concern Warning With $34.4M Cash and Nasdaq Bid-Price Deficiency
  • Context Therapeutics Plunges 30% After-Hours on Wider Loss and Pipeline Shake-Up
  • Context Therapeutics Q2 Loss Widens to $14.6M, Discontinues CT-95 Program
  • Context Therapeutics Faces Nasdaq Delisting Notice as Stock Sinks Below $1.00

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$36.12M
Diluted EPS
-$0.38
Op. Cash Flow
-$26.39M
Free Cash Flow
-$26.42M
Operating Income
-$39.7M
Cash & Equivalents
$66M
Debt / Equity
0.00×
Shares Outstanding
91.88M sh
Source: 10-K · filed 2026-03-23 · accession 0001628280-26-020498

Short Interest & Short Volume

3.68 days to cover

FINRA reported short interest of 4,695,883 shares in CNTX as of the October 30, 2026 settlement, a 9.9% increase from the prior period — about 3.7 days to cover at its recent average daily volume. On November 20, 2026, 32.7% of CNTX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)4,695,883 shares as of October 30, 2026
Change vs prior period▲ 9.9%
Days to cover3.68 at avg daily volume of 1,277,032
Daily short volume (FINRA facilities)32.7% of 453,753 shares on November 20, 2026
5-day average short volume51.0%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for CNTX, detected from its recent SEC filings · based on capital-structure filings through 2026-06-26.

Authorized Share Increase Approved · Significant Potential Dilution

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with C →
$0.16
52-week range · as of 2026-11-10 $0.16 – $3.62
Market cap
$14.7M
Volume
1.1M (0.8× avg)
3-mo avg 1.5M
Live data · 2026-11-22 00:15 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CNTX - Latest Insights

CNTX
Nov 10, 2026, 4:16 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.1875
Real-time Price: $0.160 info
Change: -$0.0275 (-15%) info
Market Cap: $14.701M info
CNTX
Nov 10, 2026, 4:12 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.1875
Real-time Price: $0.160 info
Change: -$0.0275 (-15%) info
Market Cap: $14.701M info
CNTX
Aug 06, 2026, 1:32 AM EDT
Source: Benzinga
Importance Score:
8
Price at Filing: $0.482
Real-time Price: $0.160 info
Change: -$0.322 (-67%) info
Market Cap: $14.701M info
CNTX
Aug 05, 2026, 4:58 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $0.660
Real-time Price: $0.160 info
Change: -$0.500 (-76%) info
Market Cap: $14.701M info
CNTX
Jul 31, 2026, 4:08 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.5994
Real-time Price: $0.160 info
Change: -$0.4394 (-73%) info
Market Cap: $14.701M info
CNTX
Jun 26, 2026, 4:07 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.570
Real-time Price: $0.160 info
Change: -$0.410 (-72%) info
Market Cap: $14.701M info
CNTX
Jun 15, 2026, 9:18 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.24
Real-time Price: $0.160 info
Change: -$1.08 (-87%) info
Market Cap: $14.701M info
CNTX
Jun 15, 2026, 6:30 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $1.47
Real-time Price: $0.160 info
Change: -$1.31 (-89%) info
Market Cap: $14.701M info
CNTX
May 18, 2026, 6:47 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.17
Real-time Price: $0.160 info
Change: -$2.01 (-93%) info
Market Cap: $14.701M info
CNTX
May 06, 2026, 4:10 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $2.46
Real-time Price: $0.160 info
Change: -$2.30 (-93%) info
Market Cap: $14.701M info
CNTX
May 01, 2026, 4:07 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.26
Real-time Price: $0.160 info
Change: -$2.10 (-93%) info
Market Cap: $14.701M info
CNTX
Apr 28, 2026, 4:12 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $2.51
Real-time Price: $0.160 info
Change: -$2.35 (-94%) info
Market Cap: $14.701M info
CNTX
Apr 17, 2026, 4:29 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $2.43
Real-time Price: $0.160 info
Change: -$2.27 (-93%) info
Market Cap: $14.701M info
CNTX
Apr 02, 2026, 7:41 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.73
Real-time Price: $0.160 info
Change: -$2.57 (-94%) info
Market Cap: $14.701M info
CNTX
Apr 02, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $2.72
Real-time Price: $0.160 info
Change: -$2.56 (-94%) info
Market Cap: $14.701M info
CNTX
Mar 23, 2026, 4:23 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $3.02
Real-time Price: $0.160 info
Change: -$2.86 (-95%) info
Market Cap: $14.701M info
CNTX
Mar 23, 2026, 4:22 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.02
Real-time Price: $0.160 info
Change: -$2.86 (-95%) info
Market Cap: $14.701M info
CNTX
Mar 23, 2026, 4:09 PM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $3.02
Real-time Price: $0.160 info
Change: -$2.86 (-95%) info
Market Cap: $14.701M info
CNTX
Mar 13, 2026, 4:09 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.36
Real-time Price: $0.160 info
Change: -$3.20 (-95%) info
Market Cap: $14.701M info
CNTX
Feb 27, 2026, 4:11 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.28
Real-time Price: $0.160 info
Change: -$2.12 (-93%) info
Market Cap: $14.701M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets